Review
doi: 10.3109/08830189009061767.
Peptide component vaccine engineering: targeting the AIDS virus
Affiliations
- PMID: 1722499
- DOI: 10.3109/08830189009061767
Item in Clipboard
Review
Peptide component vaccine engineering: targeting the AIDS virus
Int Rev Immunol.
1990.
Abstract
Most of the successful vaccines developed to date induce protective immunity resembling that produced by natural infection. HIV infection does not induce protective immunity. Thus, previously successful approaches based on live- or killed-virus preparations may not yield an effective and safe AIDS vaccine and many feel that a more highly engineered vaccine will be required. Synthetic peptides represent extremely powerful tools for vaccine research and construct optimization. The theory and practice of vaccine engineering using synthetic peptide components is reviewed with special emphasis on progress towards development of a vaccine for AIDS.
Similar articles
-
Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.Biotechnol Ther. 1991;2(1-2):123-35. Biotechnol Ther. 1991. PMID: 1726961 Review.
-
Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.Vaccine. 2001 Dec 12;20(5-6):813-25. doi: 10.1016/s0264-410x(01)00408-x. Vaccine. 2001. PMID: 11738745
-
Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine.Methods. 2004 Dec;34(4):476-87. doi: 10.1016/j.ymeth.2004.06.003. Methods. 2004. PMID: 15542374
-
Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.Biol Chem. 1999 Mar;380(3):353-64. doi: 10.1515/BC.1999.047. Biol Chem. 1999. PMID: 10223338
-
HIV vaccine development at Duke University Medical Center.Immunol Res. 2000;22(2-3):263-9. doi: 10.1385/ir:22:2-3:263. Immunol Res. 2000. PMID: 11339361 Review.
Cited by
-
Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1.Curr HIV Res. 2013 Sep;11(6):464-72. doi: 10.2174/1570162x113116660053. Curr HIV Res. 2013. PMID: 24033298 Free PMC article.
-
Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro.J Virol. 1995 Apr;69(4):2357-65. doi: 10.1128/JVI.69.4.2357-2365.1995. J Virol. 1995. PMID: 7533857 Free PMC article.
-
Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.Vaccine. 2009 Jan 7;27(2):243-9. doi: 10.1016/j.vaccine.2008.10.051. Epub 2008 Nov 7. Vaccine. 2009. PMID: 18996425 Free PMC article. Clinical Trial.
-
Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols.Clin Exp Immunol. 2001 Jun;124(3):445-52. doi: 10.1046/j.1365-2249.2001.01540.x. Clin Exp Immunol. 2001. PMID: 11472406 Free PMC article.
-
Fine specificity of the murine immune response to SV40 large tumour antigen utilizing synthetic peptides that define selected epitopes.Clin Exp Immunol. 1994 Jun;96(3):491-9. doi: 10.1111/j.1365-2249.1994.tb06056.x. Clin Exp Immunol. 1994. PMID: 7516272 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
